AN INNOVATIVE THERAPEUTIC SOLUTION FOR CRS

LYR-220, Lyra Therapeutics’ second product candidate, has completed Phase 2 for chronic rhinosinusitis (CRS) patients who have undergone a prior sinus surgery but continue to have persistent disease. LYR-220 is sized for patients whose nasal cavity is enlarged due to sinus surgery.

Like LYR-210 but larger, LYR-220 is a bioabsorbable nasal mesh administered in a brief in-office procedure. LYR-220 is intended to deliver up to six months of continuous, proven anti-inflammatory therapy, mometasone furoate, to the sinonasal passages of CRS patients with post-surgical anatomy.

LYR-220 was evaluated in the BEACON Phase 2 clinical trial.